Core Viewpoint - HSK47977, a novel oral BCL6 PROTAC small molecule developed by the company, has received FDA approval to proceed with clinical trials, indicating progress in lymphoma treatment [1] Group 1: FDA Approval - The company announced on September 1 that it received a Study May Proceed Letter from the FDA for HSK47977 [1] - The FDA's review confirmed that the clinical trial application for HSK47977 meets the requirements for drug registration [1] Group 2: Product Details - HSK47977 is designed to target and degrade the BCL6 protein, which is involved in the development of tumor cells [1] - The drug is intended for the treatment of lymphoma, highlighting its potential therapeutic application in oncology [1]